natgillin/translations-raw huggingface dataset:
No incompatibilities between Zirabev and polyvinyl chloride or polyolefine bags or infusion sets have been observed. 
Med zdravilom Zirabev in vrečkami iz polivinilklorida ali poliolefina ali infuzijskimi seti niso opazili nobenih inkompatibilnosti.
Eight hundred and twenty-nine patients were randomised (292 FOLFOX-4, 293 bevacizumab + FOLFOX-4 and 244 bevacizumab monotherapy). 
Randomizirali so 829 bolnikov (292 na shemo FOLFOX-4, 293 na bevacizumab + shema FOLFOX-4 in 244 na monoterapijo z bevacizumabom).
A doctor or nurse will give you this diluted Zirabev solution by intravenous infusion (a drip into your vein). 
Zdravnik ali medicinska sestra vam bosta razredčeno raztopino zdravila Zirabev dala z intravensko infuzijo (kapalna infuzija v veno).
878 patients were randomised to the two arms. 
V 2 skupini so skupno randomizirali 878 bolnikov.
MAHA is a haemolytic disorder which can present with red cell fragmentation, anaemia, and thrombocytopenia. 
MAHA je hemolitična motnja, ki se lahko kaže s fragmentacijo rdečih krvnih celic, anemijo in trombocitopenijo.
● if you develop severe high blood pressure requiring treatment with blood pressure medicines, 
● če se vam pojavi zelo visok krvni tlak, ki ga je treba zdraviti z zdravili proti povišanemu krvnemu tlaku,
Table 12 Efficacy results for trial BO17704 
Preglednica 12 Rezultati učinkovitosti v preskušanju BO17704
While the incidence of CHF was, in both arms, above that previously observed for doxorubicin therapy, the rate was higher in the R-CHOP plus bevacizumab arm. 
Medtem ko je bila pojavnost KSP v obeh skupinah večja od tiste, ki so jo predhodno opazili pri zdravljenju z doksorubicinom, je bil delež večji v skupini, ki je prejemala R-CHOP in bevacizumab.
The clinical benefit, as measured by overall survival, was seen in all pre-specified patient subgroups, including those defined by age, sex, performance status, location of primary tumour, number of organs involved and duration of metastatic disease. 
Klinično korist, ki so jo izmerili s celokupnim preživetjem, so opazili pri vseh vnaprej določenih podskupinah bolnikov, vključno s podskupinami, ki so jih osnovali glede na starost, spol, splošno stanje zmogljivosti, lokalizacijo primarnega tumorja, število prizadetih organov in trajanje metastatske bolezni.
• reduction in the number of white cells in the blood, and cells that help the blood clot, 
• zmanjšanje števila belih krvnih celic in celic, ki pomagajo pri strjevanju krvi,
You must not breast-feed your baby during treatment with Zirabev and for at least 6 months after the last dose of Zirabev, as this medicine may interfere with the growth and development of your baby. 
Med zdravljenjem z zdravilom Zirabev in še najmanj 6 mesecev po zadnjem odmerku zdravila Zirabev ne smete dojiti, saj lahko to zdravilo vpliva na rast in razvoj vašega otroka.
In clinical trials of metastatic carcinoma of the colon or rectum, there was no increased risk of post-operative bleeding or wound healing complications observed in patients who underwent major surgery 28-60 days prior to starting bevacizumab. 
V kliničnih preskušanjih pri bolnikih z metastatskem karcinomom debelega črevesa in danke niso opazili povečanega tveganja za pooperativno krvavitev ali zaplete pri celjenju ran pri bolnikih, ki so imeli 28-60 dni pred začetkom zdravljenja z bevacizumabom večji kirurški poseg.
Studies in animals have shown reproductive toxicity including malformations (see section 5.3). 
Študije na živalih so pokazale vpliv na sposobnost razmnoževanja, vključno z malformacijami (glejte poglavje 5.3).
● It is possible that Zirabev may cause bleeding in and around your brain. 
● Možno je, da zdravilo Zirabev povzroča krvavitve v možganih in okoli možganov.
Patients were treated until disease progression. 
Bolnike so zdravili do napredovanja bolezni.
If patients are experiencing symptoms that affect their vision or concentration, or their ability to react, they should be advised not to drive and use machines until symptoms abate. 
Bolnikom, pri katerih se pojavijo simptomi, ki vplivajo na vid ali koncentracijo oziroma sposobnost odzivanja, je treba svetovati, naj ne vozijo in upravljajo strojev, dokler simptomi ne izzvenijo.
Marketing Authorisation Holder Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Bruxelles, Belgium 
Imetnik dovoljenja za promet z zdravilom Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Bruxelles, Belgija
Therapy should not be initiated for at least 28 days following major surgery or until the surgical wound is fully healed. 
Zdravljenja ne smemo začeti, če je od večjega kirurškega posega minilo manj kot 28 dni oziroma dokler se kirurška rana popolnoma ne zaceli.
Once the vial has been opened, the dilution must be performed immediately. 
Po odprtju viale je treba zdravilo takoj razredčiti.
The primary outcome measure was overall survival defined as the time from randomisation until death from any cause. 
Primarno merilo izida je bilo celokupno preživetje, opredeljeno kot čas od randomizacije do smrti iz kateregakoli vzroka.
Patients and percentage of patients with best overall response of confirmed CR or PR; percentage calculated on patients with measurable disease at baseline 95% CI for one sample binomial using Pearson-Clopper method Approximate 95% CI for difference of two rates using Hauck-Anderson method log-rank test (stratified) Primary analysis was performed with a data cut-off date of 12 December 2012 and is considered the final analysis 
ocene po Kaplan-Meierjevi metodi bolnice in odstotek bolnic z najboljšim celokupnim odzivom s potrjenim CR ali PR; odstotek so izračunali pri bolnicah z merljivo boleznijo ob izhodišču 95 % IZ za binomsko porazdelitev z enim vzorcem z uporabo Pearson-Clopperjeve metode približno 95 % IZ za razliko med dvema stopnjama z uporabo Hauck-Andersonove metode log-rank test (stratificiran) primarno analizo so opravili s podatki, ki so jih zajeli do 12. decembra 2012, in velja za končno analizo nadaljnjo analizo so opravili s podatki, ki so jih zajeli do 7. marca 2014 p-vrednost je navedena samo v opisne namene
Very rare Frequency not known 
Zelo redki Neznana pogostnost
In this trial, there were two primary objectives: to show that XELOX was non-inferior to FOLFOX-4 and to show that bevacizumab in combination with FOLFOX-4 or XELOX chemotherapy was superior to chemotherapy alone. 
V tem preskušanju sta bila 2 primarna cilja: pokazati, da je shema XELOX neinferiorna shemi FOLFOX-4 in da je bevacizumab v kombinaciji s kemoterapevtsko shemo FOLFOX-4 ali XELOX superioren zdravljenju samo s kemoterapijo.
Patients with thromboembolic reactions ≤ Grade 3 need to be closely monitored (NCI-CTCAE v.3). 
Bolnike s trombemboličnimi dogodki stopnje ≤ 3 je treba skrbno spremljati (NCI-CTCAE v.3).
What you need to know before you use Zirabev 
Kaj morate vedeti, preden boste uporabili zdravilo Zirabev
a Interferon alfa-2a 9 MIU 3x/week b Bevacizumab 10 mg/kg q 2 wk 
Interferon alfa-2a 9 mio i.e. 3-krat/teden Bevacizumab 10 mg/kg vsaka 2 tedna
An exploratory multivariate Cox regression model using backward selection indicated that the following baseline prognostic factors were strongly associated with survival independent of treatment: gender, white blood cell count, platelets, body weight loss in the 6 months prior to trial entry, number of metastatic sites, sum of longest diameter of target lesions, Motzer score. 
S pomočjo raziskovalnega multivariantnega Coxovega regresijskega modela s postopnim izključevanjem so ugotovili, da so naslednji izhodiščni prognostični dejavniki močno povezani s preživetjem, neodvisno od zdravljenja: spol, število belih krvnih celic, število trombocitov, zmanjšanje telesne mase v 6 mesecih pred vključitvijo v preskušanje, število metastatskih mest, vsota najdaljših premerov tarčnih lezij, rezultat po Motzerju.
Observed effects included decreases in maternal and foetal body weights, an increased number of foetal resorptions and an increased incidence of specific gross and skeletal foetal malformations. 
Opazili so zmanjšanje telesne mase tako matere kot ploda, povečanje števila resorbiranih plodov ter povečano pojavnost določenih hujših in skeletnih nepravilnosti ploda.
Patients with NSCLC of known squamous cell histology or mixed cell type with predominant squamous cell histology were excluded from subsequent phase III trials, while patients with unknown tumour histology were included. 
Bolnike z NSCLC z znano ploščatocelično histologijo ali mešanim celičnim tipom s prevladujočo ploščatocelično histologijo so izključili iz nadaljnjih preskušanj 3. faze, vključili pa so bolnike z neznano histologijo tumorja.
For further information please refer to Table 3 ‘Adverse reactions reported in post-marketing setting.' 
Za nadaljnje informacije glejte preglednico 3 ''Neželeni učinki, o katerih so poročali v obdobju trženja''.
The addition of bevacizumab to IFL resulted in statistically significant increases in overall survival, progression-free survival and overall response rate (see Table 4). 
Dodajanje bevacizumaba shemi IFL je statistično pomembno podaljšalo celokupno preživetje, preživetje brez napredovanja bolezni in celokupni odziv na zdravljenje (glejte preglednico 4).
The primary efficacy variable of the trial was overall survival. 
Primarna spremenljivka učinkovitosti v preskušanju je bilo celokupno preživetje.
Detailed information about these post-marketing reactions are provided in Table 3. 
Natančnejši podatki o teh neželenih učinkih iz obdobja trženja so navedeni v preglednici 3.
The pharmacokinetic results show that the clearance and volume of distribution of bevacizumab were comparable between paediatric and young adult patients when normalised by body weight, with exposure trending lower as body weight decreased. 
Farmakokinetični rezultati kažejo, da sta bila po normalizaciji glede na telesno maso očistek in volumen porazdelitve bevacizumaba med pediatričnimi in mlajšimi odraslimi bolniki primerljiva, pri čemer se je izpostavljenost zmanjševala z manjšanjem telesne mase.
Across clinical trials, the following Grade 3 and 4 (NCI-CTCAE v.3) laboratory abnormalities occurred in patients treated with bevacizumab with at least a 2% difference compared to the corresponding control groups: hyperglycaemia, decreased haemoglobin, hypokalaemia, hyponatraemia, decreased white blood cell count, increased international normalised ratio (INR). 
V kliničnih preskušanjih so se naslednje laboratorijske nepravilnosti stopnje 3 in 4 (NCI-CTCAE v.3) pri bolnikih, ki so se zdravili z bevacizumabom, pojavile z najmanj 2 % razliko v primerjavi z ustreznimi kontrolnimi skupinami: hiperglikemija, zmanjšanje vrednosti hemoglobina, hipokaliemija, hiponatriemija, zmanjšanje števila belih krvnih celic, povečano internacionalno normalizirano razmerje (INR - international normalised ratio).
When used for patients with kidney cancer, it will be administered with another type of medicine called interferon. 
Kadar ga uporabljamo pri bolnikih z rakom ledvic, ga dajemo skupaj z drugo vrsto zdravila, ki se imenuje interferon.
● Zirabev can increase the incidence of high blood pressure. 
● Zdravilo Zirabev lahko poveča pojavnost visokega krvnega tlaka.
The primary endpoint of this trial was progression free survival (PFS), based on trial investigators' assessment of disease progression. 
Primarni opazovani dogodek v tem preskušanju je bilo preživetje brez napredovanja bolezni (PFSprogression-free survival) na podlagi napredovanja bolezni, kot so ga ocenili raziskovalci v preskušanju.
This has mainly been seen in combination with platinum- or taxane-based therapies in the treatment of NSCLC, mBC, and in combination with paclitaxel and topotecan in persistent, recurrent, or metastatic cervical cancer. 
To so večinoma opazili v kombinaciji z zdravljenjem na osnovi platine ali taksanov pri bolnikih z NSCLC, mBC in v kombinaciji s paklitakselom in topotekanom pri bolnicah z dolgotrajnim, ponavljajočim se ali metastatskim rakom materničnega vratu.
The addition of bevacizumab to fluoropyrimidine-based chemotherapy resulted in a statistically significant prolongation of survival in patients with mCRC who have progressed on a first-line bevacizumab-containing regimen (ITT = 819) (see Table 9). 
Dodajanje bevacizumaba kemoterapiji na osnovi fluoropirimidina je statistično pomembno podaljšalo preživetje pri bolnikih z mCRC, pri katerih je bolezen napredovala po prvi liniji zdravljenja po shemi, ki je vključevala bevacizumab (ITT = 819) (glejte preglednico 9).
An interim analysis showed there was a significant prolongation of the time to progression of disease in the 10 mg/kg group as compared with the placebo group (hazard ratio, 2.55; p < 0.001). 
Vmesna analiza je pokazala, da se je čas do napredovanja bolezni pomembno podaljšal v skupini, ki je prejemala odmerek 10 mg/kg, v primerjavi s skupino, ki je prejemala placebo (razmerje ogroženosti 2,55; p < 0,001).
Bevacizumab use has been associated with serious cases of fistulae including reactions resulting in death. 
Uporaba bevacizumaba je povezana z resnimi primeri fistul, vključno s takšnimi, ki so se končali s smrtjo.
The primary endpoint was duration of survival. 
Primarni opazovani dogodek je bilo trajanje preživetja.
In clinical trials, proteinuria has been reported within the range of 0.7% to 54.7% of patients receiving bevacizumab. 
V kliničnih preskušanjih so o proteinuriji poročali pri 0,7 % do 54,7 % bolnikov, ki so prejemali bevacizumab.
There have been rare reports of bevacizumab-treated patients developing signs and symptoms that are consistent with PRES, a rare neurological disorder. 
Pri bolnikih, ki so se zdravili z bevacizumabom, so redko poročali o pojavu znakov in simptomov, značilnih za PRES, redko nevrološko motnjo.
Depending on the dose prescribed for you, some or all of the contents of the Zirabev vial will be diluted with sodium chloride solution before use. 
Odvisno od odmerka, ki vam ga je predpisal zdravnik, je treba del ali vso vsebino viale z zdravilom Zirabev pred uporabo razredčiti z raztopino natrijevega klorida.
When events were noted as both all grade and grade 3-5 adverse drug reactions in clinical trials, the highest frequency observed in patients has been reported. 
Kadar so bili neželeni učinki v kliničnih preskušanjih vseh stopenj in stopnje 3-5, so poročali o največji pogostnosti, ki so jo opazili pri bolnikih.
Tumour-associated haemorrhage was also seen rarely in other tumour types and locations, including cases of central nervous system (CNS) bleeding in patients with CNS metastases (see section 4.4). 
S tumorjem povezano krvavitev so redkeje opazili pri bolnikih z drugimi vrstami in lokalizacijami tumorjev, vključno s primeri krvavitve v centralnem živčnem sistemu (CŽS) pri bolnikih z metastazami v CŽS (glejte poglavje 4.4).
In the majority of the occasions the necessary amount of Zirabev can be diluted with 0.9% sodium chloride solution for injection to a total volume of 100 mL. 
V večini primerov lahko potrebno količino zdravila Zirabev razredčimo z 0,9-odstotno raztopino natrijevega klorida za injiciranje do končnega volumna 100 ml.
● if you are allergic (hypersensitive) to Chinese hamster ovary (CHO) cell products or to other recombinant human or humanised antibodies. 
● če ste alergični na produkte ovarijskih celic kitajskega hrčka (CHO - Chinese hamster ovary) ali druga rekombinantna humana ali humanizirana protitelesa.
There have also been less common reactions of minor mucocutaneous haemorrhage in other locations, such as gingival bleeding or vaginal bleeding. 
Manj pogosto je prihajalo tudi do manjših kožnih in sluzničnih krvavitev na drugih mestih, na primer krvavitev iz dlesni ali krvavitev iz nožnice.
The necessary amount of bevacizumab should be withdrawn and diluted to the required administration volume with sodium chloride 9 mg/ml (0.9%) solution for injection. 
Odvzeti je treba potrebno količino bevacizumaba in jo razredčiti do ustreznega volumna za dajanje z 0,9-odstotno (9 mg/ml) raztopino natrijevega klorida za injiciranje.
Increased rates of severe neutropenia, febrile neutropenia, or infection with or without severe neutropenia (including some fatalities) have been observed mainly in patients treated with platinumor taxane-based therapies in the treatment of NSCLC and mBC. 
Opazili so povečano pogostnost hude nevtropenije, febrilne nevtropenije ali okužbe s hudo nevtropenijo ali brez nje (vključno z nekaj smrtnimi primeri), in sicer večinoma pri bolnikih, ki so prejemali zdravljenje na osnovi platine ali taksanov za NSCLC in mBC.
Adjustment for these baseline factors resulted in a treatment hazard ratio of 0.78 (95% CI [0.63; 0.96], p=0.0219), indicating a 22% reduction in the risk of death for patients in the bevacizumab + IFN alfa-2a arm compared to IFN alfa-2a arm. 
Po prilagoditvi glede na te izhodiščne dejavnike je bilo razmerje ogroženosti za zdravljenje 0,78 (95 % IZ [0,63; 0,96], p = 0,0219), kar je pomenilo 22 % zmanjšanje tveganja za smrt pri bolnikih v skupini, ki je prejemala bevacizumab + IFN alfa-2a, v primerjavi z bolniki v skupini, ki je prejemala IFN alfa-2a.
● Zirabev may increase the risk of developing serious infections of the skin or deeper layers under the skin, especially if you had holes in the gut wall or problems with wound healing. 
● Zdravilo Zirabev lahko poveča tveganje za nastanek resnih okužb kože ali globljih plasti pod kožo, zlasti če ste imeli preluknjano črevesno steno ali težave pri celjenju ran.
The recommended dose is 5 mg, 7.5 mg, 10 mg or 15 mg per kilogram of your body weight. 
Priporočeni odmerek je 5 mg, 7,5 mg, 10 mg ali 15 mg na kilogram vaše telesne mase.
In situations where early discontinuation of chemotherapy was required, treatment with bevacizumab as a single agent continued until disease progression. 
V primerih, kjer je bila potrebna predčasna prekinitev kemoterapije, so do napredovanja bolezni zdravljenje nadaljevali le z bevacizumabom.
• AVF2192g: In combination with bolus 5-FU/FA for a total of 6 weeks of each 8 week-cycle (Roswell Park regimen) in patients who were not optimal candidates for first-line irinotecan treatment. 
AVF2192g: v kombinaciji z bolusom 5-FU/FA, skupaj 6 tednov v vsakem 8tedenskem ciklu (shema Roswell Park), pri bolnikih, ki niso bili najprimernejši za prvo linijo zdravljenja z irinotekanom.
Venous thromboembolic reactions include deep venous thrombosis, pulmonary embolism and thrombophlebitis. 
Venski trombembolični dogodki vključujejo globoko vensko trombozo, pljučno embolijo in tromboflebitis.
The addition of erlotinib to bevacizumab did not result in an improvement in OS (HR = 1.764; p=0.1789), duration of objective response (6.7 vs 9.1 months) or time to symptom progression (HR = 1.172; p=0.5076). 
Dodajanje erlotiniba bevacizumabu ni prispevalo k izboljšanju OS (HR = 1,764; p = 0,1789), trajanja objektivnega odziva na zdravljenje (6,7 meseca v primerjavi z 9,1 meseca) ali časa do napredovanja simptomov (HR = 1,172; p = 0,5076).
Day 1, prior to XELOX, q 3 weeks 
1. dan, pred shemo XELOX, vsake 3 tedne
Overall response rate Rate (%) 
Celokupni odziv delež (%)
bevacizumab was combined with two chemotherapy regimens: 
Bevacizumab so kombinirali z 2 kemoterapevtskima shemama:
Seven patients in each arm had an objective response. 
Objektivni odziv na zdravljenje je doseglo 7 bolnikov iz vsake skupine.
If you have headache, vision changes, confusion or seizure with or without high blood pressure, please contact your doctor. 
Če imate glavobol, spremembe vida, ste zmedeni ali imate epileptični napad z visokim krvnim tlakom ali brez njega, se obrnite na zdravnika.
• reduced blood supply to the brain or stroke, 
• zmanjšan dotok krvi v možgane ali možgansko kap,
Hypersensitivity reactions/infusion reactions (see section 4.4 and Post-marketing experience below) 
Preobčutljivostne reakcije/reakcije na infuzijo (glejte poglavje 4.4 in ''Izkušnje v obdobju trženja'' spodaj)
Post-marketing adverse reactions are included in both Tables 1 and 2, where applicable. 
Neželeni učinki iz obdobja trženja zdravila so vključeni v preglednici 1 in 2, kot je ustrezno.
19% of the patients had received prior chemotherapy and 14% prior radiotherapy. 
19 % bolnikov je predhodno prejemalo kemoterapijo, 14 % pa obsevalno zdravljenje.
In the bevacizumab-containing arms, patients could receive bevacizumab as a single-agent every 3 weeks until disease progression or unacceptable toxicity. 
V skupinah, ki sta prejemali bevacizumab, so bolniki lahko prejemali bevacizumab samostojno vsake 3 tedne do napredovanja bolezni ali do nesprejemljive toksičnosti.
The European Medicines Agency has waived the obligation to submit the results of studies, in all subsets of the paediatric population, in breast carcinoma, adenocarcinoma of the colon and rectum, lung carcinoma (small cell and non-small cell carcinoma), kidney and renal pelvis carcinoma (excluding nephroblastoma, nephroblastomatosis, clear cell sarcoma, mesoblastic nephroma, renal medullary carcinoma and rhabdoid tumour of the kidney), ovarian carcinoma (excluding rhabdomyosarcoma and germ cell tumours), fallopian tube carcinoma (excluding rhabdomyosarcoma and germ cell tumours), peritoneal carcinoma (excluding blastomas and sarcomas) and cervix and corpus uteri carcinoma. 
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij za vse podskupine pediatrične populacije pri karcinomu dojk, adenokarcinomu debelega črevesa in danke, karcinomu pljuč (drobnoceličnem in nedrobnoceličnem karcinomu), karcinomu ledvic in ledvičnega meha (razen nefroblastoma, nefroblastomatoze, svetloceličnega sarkoma, mezoblastnega nefroma, karcinoma ledvične sredice in rabdoidnega tumorja ledvic), karcinomu jajčnikov (razen rabdomiosarkoma in germinalnih tumorjev), karcinomu jajcevodov (razen rabdomiosarkoma in germinalnih tumorjev), peritonealnem karcinomu (razen blastoma in sarkoma) ter karcinomu materničnega vratu in materničnega telesa.
The pharmacokinetics of bevacizumab was well characterized by the paediatric population PK model for 70 patients in Study BO20924 ((1.4 to 17.6 years; 11.6 to 77.5 kg) and 59 patients in Study BO25041 (1 to 17 years; 11.2 to 82.3 kg). 
Farmakokinetiko bevacizumaba so dobro opredelili z uporabo farmakokinetičnega modela pediatrične populacije pri 70 bolnikih v študiji BO20924 (od 1,4 leta do 17,6 leta; od 11,6 kg do 77,5 kg) in 59 bolnikih v študiji BO25041 (od 1 leta do 17 let; od 11,2 kg do 82,3 kg).
Bevacizumab binds selectively to a protein called human vascular endothelial growth factor (VEGF), which is found on the lining of blood and lymph vessels in the body. 
Bevacizumab se selektivno veže na beljakovino, imenovano humani vaskularni endotelijski rastni faktor (VEGF - vascular endothelial growth factor), ki se nahaja na notranji steni krvnih in limfnih žil v telesu.
The efficacy and safety of bevacizumab in combination with chemotherapy (paclitaxel and cisplatin or paclitaxel and topotecan) in the treatment for patients with persistent, recurrent or metastatic carcinoma of the cervix was evaluated in study GOG-0240, a randomised, four-arm, open label, multi- centre phase III trial. 
Učinkovitost in varnost bevacizumaba v kombinaciji s kemoterapijo (paklitaksel in cisplatin ali paklitaksel in topotekan) za zdravljenje bolnic z dolgotrajnim, ponavljajočim se ali metastatskim karcinomom materničnega vratu, so ocenjevali v študiji GOG-0240, randomiziranem, odprtem, multicentričnem preskušanju 3. faze s 4 skupinami.
a 5 mg/kg every 2 weeks. 
5 mg/kg vsaka 2 tedna.
Proteinuria ranged in severity from clinically asymptomatic, transient, trace proteinuria to nephrotic syndrome, with the great majority as Grade 1 proteinuria (NCI-CTCAE v.3). 
Proteinurija je po resnosti segala od klinično asimptomatske proteinurije, prehodne proteinurije, proteinurije v sledovih do nefrotskega sindroma; večinoma je šlo za proteinurijo stopnje 1 (NCICTCAE v.3).
● severe high blood pressure which cannot be controlled by blood pressure medicines; or a sudden severe rise in blood pressure, 
● zelo visok krvni tlak, ki ga ni mogoče obvladati z zdravili proti zvišanemu krvnemu tlaku,
The side effects listed below were seen when bevacizumab was given together with chemotherapy. 
Spodaj navedene neželene učinke so opazili, ko so bevacizumab dajali skupaj s kemoterapijo.